Clinical trials: Pembrolizumab
HNSCC
Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma
This trial evaluates the addition of pembrolizumab to standard postoperative adjuvant radiochemotherapy in the treatment of patients with locally advanced intermediate and high risk head and neck squamous cell carcinoma (HNSCC).
- Trial name
- NCT03480672
- Testing
- Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA], adjuvant radiochemotherapy
- Where
- 16 sites in Germany
- Volunteers
- 211 people
- Sponsor
- University of Leipzig
Adrenocortical Carcinoma
Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.
This study is a national, multicenter, interventional, phase II clinical trial on the use of pembrolizumab in advanced adrenocortical carcinoma, with confirmed progression within 6 months, following EDP or EDP-M ( etoposide…
- Trial name
- PEMBR-01 (NCT05563467)
- Testing
- Pembrolizumab 25 MG/ML [Keytruda]
- Where
- 4 sites in Poland
- Volunteers
- 24 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
Mucosal Melanoma of the Head and Neck
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
This is an open-label, single center, one cohort, non-randomized, phase II study. The aim is to evaluate the efficacy and safety of the combination of hypofractionated radiotherapy (HRT) and pembrolizumab on local tumor control…
- Trial name
- NCT04318717
- Testing
- Pembrolizumab, Hypofractionated radiation therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Advanced Cancer
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
RBS2418 (investigational product) is a specific immune modulator, working through ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1), designed to lead to anti-tumor immunity by increasing endogenous 2'-3'-cyclic guanosine…
- Trial name
- NCT05270213
- Testing
- RBS2418, Pembrolizumab, Other approved anti-cancer therapy
- Where
- 14 sites in United States
- Volunteers
- 164 people
- Sponsor
- Riboscience, LLC.
Advanced Non-small Cell Lung Cancer
The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer
This is a phase 2 study to investigate NC318 alone or in combination with Pembrolizumab in patients with advanced non-small cell lung cancer.
- Trial name
- NCT04699123
- Testing
- NC318 800 mg, NC318 400 mg, Pembrolizumab
- Where
- United States
- Volunteers
- 159 people
- Sponsor
- Yale University
Squamous Cell Carcinoma of Head and Neck
A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer
The primary objective of this study was to estimate the response rate to ALKS 4230 in combination with pembrolizumab in patients with HNSCC who had previously received anti-PD-(L)1 therapy but who had not achieved a CR.
- Trial name
- NCT04144517
- Testing
- Nemvaleukin Alfa, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 14 people
- Sponsor
- Mural Oncology, Inc
Non-small Cell Lung Cancer
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement [N2])…
- Trial name
- INTerpath-002 (NCT06077760)
- Testing
- Intismeran autogene, Pembrolizumab
- Where
- 229 sites in United States, Argentina and 31 more
- Volunteers
- 868 people
- Sponsor
- Merck Sharp & Dohme LLC
Endometrial Neoplasms
Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])
This is a study of pembrolizumab (MK-3475, KEYTRUDA®) in combination with lenvatinib (E7080) versus treatment of physician's choice (doxorubicin or paclitaxel) for the treatment of advanced endometrial cancer.
- Trial name
- NCT03517449
- Testing
- Pembrolizumab, Lenvatinib, Paclitaxel
- Where
- 169 sites in United States, Argentina and 19 more
- Volunteers
- 827 people
- Sponsor
- Eisai Inc.
Non-Small Cell Lung Cancer
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Non-Squamous Non-Small Cell Lung Cancer (NSCLC) remains a leading cause of cancer mortality worldwide, with poor survival prospects for metastatic disease.
- Trial name
- LIVIGNO-4 (NCT06236438)
- Testing
- Livmoniplimab, Budigalimab, Pembrolizumab
- Where
- 61 sites in United States, Australia and 10 more
- Volunteers
- 167 people
- Sponsor
- AbbVie
Colon Cancer
Pembrolizumab in Early Stage Colon Cancer
This study will gather information on the safety and effectiveness of pembrolizumab, an immunotherapy drug. The purpose of this study is to target early stage colon cancer before it has developed resistance to immunotherapy.
- Trial name
- NCT04231526
- Testing
- Pembrolizumab, Surgery
- Where
- 2 sites in United States
- Sponsor
- University of Chicago
Head and Neck Cancer, Malignant Melanoma
GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
The purpose of this study is to measure safety, tolerability, and preliminary antitumor efficacy of GM103 administered alone and in combination with pembrolizumab in patients with locally advanced, unresectable, refractory and/or…
- Conditions
- Head and Neck Cancer, Malignant Melanoma, Colorectal Cancer, Renal Cell Carcinoma
- Trial name
- NCT06265025
- Testing
- GM103 (Part A), GM103 (Part B), GM103 and Pembrolizumab (Part C)
- Where
- 4 sites in South Korea
- Volunteers
- 125 people
- Sponsor
- GeneMedicine Co., Ltd.
Colorectal Cancer; Lung Cancer
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.
- Trial name
- NCT04701476
- Testing
- TATE and pembrolizumab, TAS-102 pill, Regorafenib Pill
- Where
- 3 sites in United States, Taiwan
- Volunteers
- 110 people
- Sponsor
- Teclison Ltd.
Glioblastoma
Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma
This research study is studying pembrolizumab and re-irradiation as possible treatments for glioblastoma. The drugs involved in this study are: Pembrolizumab Radiation Bevacizumab, an FDA-approved drug for treating recurrent…
- Trial name
- NCT03661723
- Testing
- Pembrolizumab, Bevacizumab, Re-irradiation
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Dana-Farber Cancer Institute
Carcinoma, Non-Small-Cell Lung
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with…
- Trial name
- NCT06875310
- Testing
- Adagrasib, Pembrolizumab, Carboplatin
- Where
- 317 sites in United States, Argentina and 33 more
- Volunteers
- 630 people
- Sponsor
- Mirati Therapeutics Inc.
Head and Neck Squamous Cell Carcinoma
Pembrolizumab in Combination With Low-dose PFas Neoadjuvant Treatment for Locally Advanced HNSCC
A phase Ⅱ open label multi-cencter clinical trail to evaluate the efficacy and safety of pembrolizumab combined with low-dose PF (cisplatin + 5-fluorouracil) in the neoadjuvant treatment of locally advanced head and neck squamous…
- Trial name
- NCT05446467
- Testing
- pembrolizumab+cisplatin + 5-FU
- Where
- 7 sites in China
- Volunteers
- 80 people
- Sponsor
- Zhejiang Provincial People's Hospital
Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma
Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer
This phase I trial tests the safety, side effects, and best dose of tazemetostat in combination with topotecan and pembrolizumab in treating patients with small cell lung cancer that has come back after a period of improvement…
- Conditions
- Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Platinum-Resistant Lung Small Cell Carcinoma, Platinum-Sensitive Lung Small Cell Carcinoma
- Trial name
- NCT05353439
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 15 sites in United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Or Metastatic Merkel Cell Carcinoma
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
This Phase 2/3, multicenter, randomized, double-blind, placebo-controlled trial will evaluate the Objective Response Rate (ORR) of IFx-Hu2.0 as an adjunctive therapy to pembrolizumab in adult participants (≥18 years) with…
- Trial name
- NCT06947928
- Testing
- IFx-Hu2.0, Pembrolizumab
- Where
- 18 sites in United States
- Volunteers
- 118 people
- Sponsor
- TuHURA Biosciences, Inc.
Clear Cell Tumor, Gynecologic Cancer
A Study of Pembrolizumab in Patients With Advanced Gynaecological Clear Cell Cancer
PEACOCC is a multi-centre, single arm, single stage phase II trial. The overall aim is to determine whether treatment with pembrolizumab is effective in patients with advanced clear cell gynaecological cancer.
- Conditions
- Clear Cell Tumor, Gynecologic Cancer, Advanced Cancer
- Trial name
- PEACOCC (NCT03425565)
- Testing
- Pembrolizumab
- Where
- 5 sites in United Kingdom
- Volunteers
- 48 people
- Sponsor
- University College, London
Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy [cisplatin and carboplatin] plus radiation therapy) after surgery in treating patients with head and neck squamous cell…
- Conditions
- Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT04671667
- Testing
- Carboplatin, Cisplatin, Computed Tomography
- Where
- 178 sites in United States
- Volunteers
- 188 people
- Sponsor
- National Cancer Institute (NCI)
Small Cell Ovarian Carcinoma
Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT
Small cell ovarian carcinomas are rare and have a very poor prognosis affecting a young population. The objective of this study is to increase the efficacy of the initial chemotherapy by providing immunotherapy and to be able to…
- Trial name
- PembroSCCOHT (NCT04602377)
- Testing
- Pembrolizumab 25 MG/ML [Keytruda]
- Where
- 13 sites in France
- Volunteers
- 27 people
- Sponsor
- ARCAGY/ GINECO GROUP
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.